UBS raised the firm’s price target on Aveanna (AVAH) to $6.75 from $5 and keeps a Sell rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna upgraded to Outperform from Market Perform at Raymond James
- Aveanna Healthcare Highlights Strong Financial Performance
- Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook
- Apple invests extra $100B in U.S., Trump wants Intel CEO to resign: Morning Buzz
- Aveanna Healthcare Reports Strong Q2 2025 Financial Growth